This hypoxia-driven metabolic reprogramming has been linked to resistance against a wide range of chemotherapeutic agents and targeted therapies, including HER2 inhibitors and hormonal therapies in BC [86,87]. The gene discussed is ERBB2; the disease is breast cancer.